KRAS and carcinoma: This includes the amplification ofERBB2 (11%) andERBB3 (5%), and mutations ofERBB2 (4%),ERBB3 (7%),KRAS (9%), andBRAF (2%).97 A whole genome sequencing of serum samples from the Korean patients diagnosed with OCCC revealed somatic mutation observed in genes that includePIK3CA (40%),ARID1A (40%), andKRAS (20%) in about 15 patients that correlates withPI3K/AKT,TP53, andERBB2 pathways.138 In a retrospective analysis,KRAS mutations were detected among the Japanese patients in cells isolated from the regions of endometriosis adjacent to the site of carcinoma.